Asarina Pharma Phase IIB Study receives surge in applicants volunteering for new PMDD treatment—on its first day live
Stockholm – April 16, 2018. In just one day 29 patients passed the first screening stage of the trial for the world’s first PMDD therapy. Asarina Pharma CEO Peter Nordkild: “This reflects the desperate need for a dedicated therapy for this devastating form of PMS—and the huge market potential.”The phase IIB study aims to recruit 225-250 patients in total from Sweden, UK, Germany and Poland. Successfully approving 29 patients to begin the trial process on the first day alone is significant, says Nordkild: “4-5% of women of a fertile age suffer from PMDD today, and yet they’re mostly being